Search

everythinglearnresearchcommunity

for

Search:↓

Interferons are effective for some skin conditions and cancers, but can have side effects and need more research for optimal use.

Tofacitinib, a JAK inhibitor, improved hair regrowth in most patients with severe alopecia areata and had minimal side effects.

Higher granulysin levels in the blood are linked to more severe hair loss in alopecia areata patients, and these levels decrease after effective treatment.

Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.

The secretome from mesenchymal stem cells is a promising treatment that may repair tissue and avoid side effects of stem cell transplantation.

Restoring hair bulb immune privilege is crucial for managing alopecia areata.

Topical tofacitinib may grow hair better than minoxidil by increasing VEGF and reducing inflammation.

Frontal Fibrosing Alopecia's cause is unclear, affects mainly postmenopausal women, and current treatments focus on stopping hair loss rather than regrowth.

Robotic hair transplantation with AI offers more reliable, precise, and efficient hair restoration.

There are many treatments for common hair loss, but more trials are needed to decide which are best.

The model and estimator can predict drug exposure in kidney transplant patients well.

Topical tofacitinib is effective and safe for treating alopecia areata.

Dupilumab helped a 4-year-old grow hair back after another treatment failed.

Ruxolitinib helped a man regrow his beard after years of hair loss.

Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.

Intestinal intraepithelial lymphocytes are crucial for gut immunity and maintaining the mucosal barrier.

Skin aging is a complex process influenced by various factors, leading to wrinkles and sagging, and should be considered a disease due to its health impacts.

Combination therapies for androgenetic alopecia work best but can have significant side effects and costs.

Personalized medicine in dermatology uses molecular biomarkers to improve diagnosis and treatment but needs further advancements for practical use.

A new drug, abrocitinib, helped a child with severe hair loss regrow hair.

Baricitinib may effectively treat oral lichen planus.

Baricitinib quickly improved severe alopecia areata, with almost total hair regrowth in three months.

Baricitinib helps with severe hair loss, negative-pressure therapy lowers hernia recurrence, tranexamic acid reduces bleeding, robot-assisted breast surgery may improve outcomes, and acellular dermal matrix could decrease breast reconstruction complications.

The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.

Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.

Ritlecitinib effectively improves hair growth in alopecia areata patients, regardless of hair loss pattern.

People with Alopecia Areata have more herpes simplex infections but similar rates of cancer, blood clots, and heart disease compared to those without it.

A new mutation in the STING protein causes a range of symptoms and its severity may be affected by other genetic variations; treatment with a specific inhibitor showed improvement in one patient.

Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.

Baricitinib was effective in treating a patient with dermatomyositis and hair loss.